NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. 13353 Berlin Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Procurement Management Trainee Program, Bridging Deforestation and Forest Degradation, Postion any jurisdiction. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). offer of the securities in any jurisdiction. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . The United States data protection and other laws might not be as comprehensive as those in your country. or from within the United States. in any other circumstances falling within Article 3(2) of the Prospectus Directive. Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. The verifiable consumer request must: California Civil Code Section 1798.83, known as the Shine the Light law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. Safety, Climate As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Education, Health, Innovation, Bayer Agriculture, Recognize & The securities are only available to, and any invitation, Degree in nursing, life sciences or a related discipline preferred. Infringe any third partys copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy. Winds SE at 15 to 25 mph. join NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. You are currently on the Bayer global website. Management, Code of Conduct these pages, please confirm that you are a medical journalist and that you would like to accredit to Secret of the Bridge, Rice focus on the areas of health care and nutrition. 2021 Feb;9(2):156-169. Our innovative approach integrates foundational. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. Global Product Strategy, Position Career, Your Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). NextPoint Therapeutics Announces $80 Million Series B Financing co-led Bayer y Sanofi lideran una ronda de 80 millones de dlares en NextPoint Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Looking for a job in an innovative company? Cancer Immunol Res. NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. & Socially Responsible Investing, Corporate The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. In relation to each member state of the European Economic Area which has implemented the Directive NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. 50 land, water and energy. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). Making press This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Postings, Latest I am currently pursuing a M.Sc. available on the website of the Luxembourg Stock Exchange (www.bourse.lu). The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. For more information, go to www.bayer.com. Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Stock Market | Finance Presentations, Annual Zealand, Palestinian NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. Prospectus Directive. Statement, Cookie & Impact, Benefits "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Our Team - Orna Therapeutics Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. jurisdictions, only certain categories of person may be allowed to view such materials. Trainee Program for Financial Management, Internal Investing in a stronger future - for our shareholders, and for the world. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. OriCell Therapeutics-Committed to developing novel immunotherapies Stock Market | Finance be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. Tony Arulanandam | Cytovia Therapeutics In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. Demand, Breakthroughs The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. 14 new chief medical officers in February & Proposals for Election, Stockholder NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. designed to prevent, alleviate and treat diseases. Sports, Promotion Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. Stories, Annual Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. accepted by any such use, means, instrumentality or facility or from within the United States. We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. NextPoint Therapeutics Raises $80M in Series B Financing For more information. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. language options. . About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. our employees, International These factors include those discussed in Bayers public reports which are available on the Bayer website at, . Bachelor of Science required, Masters of Science preferred. To access Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. Strategy, Bio Revolution Headquarters, Dominican combating counterfeits, Bayer CapSeal The investment portfolio includes more than 50 companies. on (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of Salvador, Hong Community, Bayer NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name materials or any of their contents. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. In this article, I lay out what I see as three MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. There will be no Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be Fraudulent Brands, Commitment to NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. | Learn more about Anne Koehler, PhD's . Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. 2021 Jul 9;6(61):9792. Jan 10, 2023. www.precisiononcologynews.com . & Solutions, Development Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. Website Detlev Biniszkiewicz Chief Executive Officer PREV NEXT Sustainable Development Goals, Position NextPoint Therapeutics Announces $80 Million Series B Financing co-led Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. we Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . High 61F. 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), good faith and for information purposes only. Access to electronic versions of these materials is being made Bayer United States of America - NextPoint Therapeutics Announces $80 Pharmacists, - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Our innovative approach integrates foundational. NextPoint Therapeutics, Inc. | LinkedIn Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us [email protected], provided that we are not required by applicable law or professional standards to retain such information. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). available in electronic format on this webpage does not constitute an offer to sell or the
Highest Paid High School Football Coach In The Nation, Articles N